Navigation Links
Ludwig Institute for Cancer Research and Polaris Group Form Collaboration to Expand Development of Polaris' Novel Cancer Drug, ADI-PEG 20
Date:5/18/2011

NEW YORK and SAN DIEGO, May 18, 2011 /PRNewswire/ -- Ludwig Institute for Cancer Research LTD (LICR) and Polaris Group (Polaris) today announced the formation of a collaboration to expand development of Polaris' novel cancer drug, pegylated arginine deiminase (ADI-PEG 20). ADI-PEG 20 kills tumor cells by depletion of the amino acid arginine.

As part of the collaboration, LICR and Polaris will explore further the potential of ADI-PEG 20 as a cancer therapy and aim to identify other amino acid-degrading enzymes with anti-tumor activity.  The collaboration builds on an existing relationship under which LICR and Polaris have studied ADI-PEG 20 in melanoma and are currently conducting a Phase 2 clinical trial in small cell lung cancer (SCLC) that was initiated in December 2010.  LICR is the sponsor of the SCLC clinical trial, and LICR and Polaris are sharing expenses and resources to conduct this trial.

"We are delighted to have this agreement with Polaris," said Andrew Simpson, Ph.D., Scientific Director of LICR. "This collaboration builds on the work of Lloyd Old, M.D. of LICR and his seminal work on amino acid-degrading enzymes, including asparaginase and arginine deiminase, as anti-cancer treatments. We look forward to continuing our close working relationship with Polaris."

Bor-Wen Wu, Ph.D., Chief Executive Officer of Polaris, said, "This agreement is the fruit of many years of collaboration between LICR and Polaris, and is an opportunity to leverage the strengths of both organizations to attempt to bring ADI-PEG 20 to patients. In particular, I would like to thank Dr. Old for his vision, guidance and dedication to this project, and to his mentoring as we have moved ADI-PEG 20 from pre-clinical studies into human clinical trials."

Dr. Old commented: "The actions of antibodies and enzymes are remarkable for their high degree of specificity, and it is this property that makes them so attractive as potential anti-cancer agents
'/>"/>

SOURCE Polaris Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Polaris Group and The Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI-PEG 20, in Patients with Small Cell Lung Cancer
2. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
3. Larta Institute Receives Award for National Institutes of Health Commercialization Assistance Program at 2011 Acquisition, Grants, and Small Business Symposium
4. Van Andel Institute Earns Highest "Green Building" Award
5. LifeNet Health Breaks Ground on New Institute of Regenerative Medicine
6. The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting
7. MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute
8. IBM and The Institute of Bioengineering and Nanotechnology Find Breakthrough for MRSA Treatment
9. Ontario Institute for Cancer Research Announces Investment in Microfluidics Technology for the Discovery of Anti-Cancer Drugs
10. Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program
11. Koch Institute for Integrative Cancer Research Dedicated Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 Research and Markets ... of the "Technology Innovations in Smart Fabrics ... http://photos.prnewswire.com/prnh/20130307/600769 ... Fabrics" offers a detailed assessment on technological advancements ... Findings: 1. The Smart Fabrics ...
(Date:12/19/2014)... December 18, 2014 LayerBio is an ... and wound care. The National Eye Institute (NEI) at ... a Phase I SBIR grant to develop a drug-eluting ... the most common cause of vision loss in people ... worldwide. According to Dr. Ken Mandell, LayerBio’s Founder and ...
(Date:12/19/2014)... December 18, 2014 iLab Solutions, the ... appointment of Siri Bryant as the new Director of ... of Core Implementations. These two new leadership positions were ... service by ensuring that iLab continues to meet the ... last four years, iLab has been deployed at over ...
(Date:12/19/2014)... 18, 2014 With only 2 weeks ... special on Sartorius Biohit products . The product specials ... Picus Electronic Pipette Trade-in Program, and free pipette tips. ... officers around the world. They are ideal for lab ... include:, ,     Full volume range of 0.1 ...
Breaking Biology Technology:Technology Innovations in Smart Fabrics (Technical Insights) 2LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2
... eResearchTechnology,Inc. (eRT), (Nasdaq: ERES ), a leading ... today that it will release its 2008 first ... on Monday, May 5,2008 after the market closes.,After ... call at 5:00 PM ET,later that day., ...
... - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... St. James,s University Hospital in Leeds,U.K. published the ... May 1, 2008,online issue of The Journal of ... Cells to Promote Innate Antitumor Immunity.", The ...
... April 23 SectorWatch.biz announces the,availability of ... and driving,markets today within the biotechnology and ... the aforementioned equities and the,opportunity for investors ... the,subject and sector., Investors can view ...
Cached Biology Technology:eResearchTechnology, Inc. to Announce 2008 First Quarter Results on May 5, 2008 2Oncolytics Biotech Inc. Announces Journal of Immunology Publication on Reovirus Activation of Dendritic Cells 2SectorWatch.biz Issues MarketStats on KBLB, DGX, LH, BRLI, and ABT 2SectorWatch.biz Issues MarketStats on KBLB, DGX, LH, BRLI, and ABT 3
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... A team of cardiologists, materials scientists, and bioengineers ... device for measuring the heart,s electrical output that they ... new device represents the first use of flexible silicon ... believe that this technology may herald a new generation ...
... ngeles Mena, Researcher at Centro de Investigacin Biomdica ... of the Neuropharmacology Laboratory at Hospital Ramn y ... predoctoral student Juan Perucho and others. The ... changes and amyloid pathology of Alzheimer,s disease in ...
... PITTSBURGH, March 24 An experimental vaccine against an ... delay the onset of inflammatory bowel disease (IBD) and in ... the University of Pittsburgh School of Medicine. Their findings are ... journal of the American Association for Cancer Research. People ...
Cached Biology News:New tissue-hugging implant maps heart electrical activity in unprecedented detail 2New tissue-hugging implant maps heart electrical activity in unprecedented detail 3Anesthesia increases risk of developing Alzheimer's disease in patients with genetic predisposition 2Anesthesia increases risk of developing Alzheimer's disease in patients with genetic predisposition 3Vaccine could delay bowel inflammation and colon cancer, says Pitt research 2
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
Biology Products: